Next-generation antibody and peptide aptamer drug discovery business!
Our company is engaged in drug discovery business for next-generation antibodies and peptide aptamers through in-house research, joint research, and alliances. Under the NEDO Research and Development Venture Support Program (STS) for the fiscal year 2017, we successfully automated the "genotype/phenotype molecular matching technology," one of the evolving molecular engineering technologies, enabling the automated preparation of a homogeneous cDNA display library with a diversity of 10^14 (hundreds of trillions). In addition to the naive VHH gene library through a technical partnership with RePHAGEN, we also possess a high-quality peptide gene library in-house. *For more details, please contact us.
Inquire About This Product
basic information
【Drug Discovery Pipeline】 ■ Drug discovery using multi-specific binding sites (multi-specific VHHs, multi-paratopic VHHs, etc.) ■ Drug discovery through allosteric action ■ Drug discovery via agonist action ■ Drug discovery using targeting VHHs ADC/phototherapy/imaging diagnostics ■ Drug discovery for intrabody targeting ■ Drug discovery with VHHs that have enzymatic activity ■ Application to cell therapy and gene therapy *For more details, please contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please contact us.
catalog（1）
Download All Catalogs
Company information
Our company is engaged in research and development in biotechnology. We are developing biomolecules that serve as alternatives to conventional antibodies, as well as biomolecules that lead to the development of therapeutics for diseases with high unmet medical needs that cannot be addressed by traditional antibody drugs. Furthermore, we are working on biomolecules that demonstrate efficacy based on new therapeutic concepts and contribute to improving socioeconomic conditions. We will implement next-generation antibodies, specifically VHH and peptide aptamers, into society and strive to create a prosperous community.